Date: 2016-06-06
Type of information: Collaboration agreement
Compound: CAP® technologies including CAP® GT expression system for gene therapy and CAP®Go for glycoproteins
Company: CEVEC Pharmaceuticals (Germany) Paragon Bioservices (USA - MD)
Therapeutic area: Technology - Services
Type agreement: collaboration production manufacturing
Action mechanism:
Disease:
Details: * On June 6, 2016, Cevec Pharmaceuticals and Paragon Bioservices announced that the companies signed a collaboration and license agreement to jointly establish CEVEC's proprietary CAP® technologies as a new industry standard for the scalable production of viral gene therapy vectors in North America. Under the terms of the agreement, CEVEC and Paragon will co-market CEVEC's proprietary CAP® technologies-including both the CAP® GT expression system for gene therapy and CAP®Go for glycoproteins-as well as Paragon's capabilities and expertise regarding CAP®-based research and development services in North America.
CEVEC will recommend that its licensees use Paragon as its preferred partner for CDMO services in North America. Additionally, CEVEC and Paragon will jointly develop and market scaled-up clinical production processes for adenovirus, adeno associated virus and lentivirus-based gene therapy vectors using the CAP®GT platform.
CEVEC will bring in its expertise regarding the evaluation and development of selected CAP® cell lines, including the development of viral packaging and producer cell lines. Paragon will provide CDMO services to CEVEC's North American CAP® technology licensees, including manufacture of CAP®GT-derived materials for use in preclinical studies, as well as in phase I and phase II clinical trials.
Financial terms: Financial details of this agreement were not disclosed.
Latest news:
